Yale pins part of calorie restriction's benefit on one protein, and it comes from fat, not liver

The human half of this finding and the causal half are not the same experiment. Falling C3 in plasma is an association measured while people ate less ^[5]. The claim that C3 *does* something is carried by mice, where the protein climbs with age and blocking it brings inflammation down ^[9][2]. Nobody here lowered C3 in a human being and measured an outcome, which is the step that turns a marker into a target.

The screen wants careful reading too. More than 7,000 proteins were measured ^[5], and C3 was pulled out partly because complement activation had already been proposed as a contributor to the chronic inflammation of aging ^[6]. That prior suspicion is what makes the hit credible, not the width of the panel. A co-first author says the causal effects of C3 in aging and chronic inflammation had not been identified before this work ^[7]. Calorie restriction earned its reputation on lifespan extension in mice, rhesus monkeys and fruit flies ^[14], and none of that named a mediator.

The tissue result is the part with engineering consequences. Complement proteins are mainly made in the liver, which is why Mishra says the team did not expect visceral white adipose tissue to be a major source of the age-related rise ^[9][11], and single-cell sequencing put production in age-associated macrophages inside that fat ^[10]. A compound that suppresses hepatic complement output would be working the wrong compartment. Circulating C3 also stops being a clean readout of where the protein came from.

Then the arithmetic behind the framing. The harms that make a drug preferable to a diet come from mice at 40 percent fewer calories, which are more vulnerable to infection, reproduce less successfully and grow poorly ^[12]. That deficit is roughly 2.9 to 3.6 times the 11 to 14 percent the CALERIE participants ate ^[17], and Yale's own earlier human work at 14 percent for two years reported stronger immune defenses without growth or reproductive problems ^[13]. At human doses the toxicity argument thins. What remains is that almost nobody sustains a 14 percent cut for two years outside a supervised trial, which is an adherence problem rather than a safety one. A C3 blocker would be a fix for compliance first.

Whether it fixes anything else is unsettled. The next question in the Yale account is whether reducing C3 helps independent of weight loss, and the account breaks off there ^[18]. If the answer is no, C3 is a downstream reading of losing fat, and the target is the fat. Dixit's line that aging is malleable and can be targeted ^[15] holds for mice until someone lowers C3 in a person and measures something that matters.